References
- Gertz M A, Kyle R A, Greipp P R. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257–262
- Kyle R A, Gertz M A, Greipp P R, Witzig T E, Lust J A, Lacy M Q, Themeau T M. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and pred‐nisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207
- Dhodapkar M, Jagannath S, Vesole D, Munshi N, Naucke S, Tricot G, Barlogie B. Treatment of AL‐amyloidosis with dexamethasone plus alpha interferon. Leuk Lym‐phoma 1997; 27: 351–356
- Gertz M A, Lacy M Q, Lust J A, Greipp P R, Witzig T E, Kyle R A. Phase II trial of high‐dose dexamethasone for previously treated immunoglobulin light‐chain amyloidosis. Am J Hematol 1999; 61: 115–119
- Comenzo R L, Falk R H, Sanchorawala V, Seldin D C, Akpek G, Malek K, Vosburgh E, Dember L, Berk J, Finn K, Fisher C, Wright D G, Skinner M. Treating Al Amyloidosis (AL) With Dose‐Intensive Melphalan: Outcomes In 102 Patients. Blood 1998; 92: 1328a, 10, Suppl 1
- D'Amato R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085
- Hideshima T, Chauhan D, Shima Y, Raje N, Davies F E, Tai Y T, Treon S P, Lin B, Schlossman R L, Richardson P, Muller G, Stirling D I, Anderson K C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 95: 2943–2950
- Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
- Rajkumar S V, Dispenzieri A, Fonseca R, Lacy M Q, Geyer S, Lust J A, Kyle R A, Greipp P R, Gertz M A, Witzig T E. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274–1276
- Seldin D C, Choufani E B, Dember L M, Wiesman J F, Berk J L, Faok R H, O'Hara C, Fennessey S, Finn K T, Wright D G, Skinner M, Sanchorawala V. Tolerability and efficacy of thalidomide for the treatment of patents with light chain‐associated (AL) amyloidosis. Clinical Lymphoma 2003; 3: 241–246
- Johnston R E, Abdalla S H. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 2002; 43: 351–354
- Pini M, Baraldi A, Pietrasanta D, Allione B, Depaoli L, Salvi F, Levis A. Haematologica, 85: 1111–1112
- Rajkumar S V, Hayman S, Gertz M A, Dispenzieri A, Lacy M Q, Greipp P R, Geyer S, Iturria N, Fonseca R, Lust J A, Kyle R A, Witzig T E. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323
- Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19